## **Co-development of gut microbial metabolism and visual neural circuitry over human infancy** Kevin S. Bonham<sup>1\*</sup>, Emma T. Margolis<sup>2\*</sup>, Guilherme Fahur Bottino<sup>1</sup>, Ana Sobrino<sup>2</sup>, Fadheela Patel<sup>3</sup>, Shelley McCann<sup>1</sup>, Michal R. Zieff<sup>4</sup>, Marlie Miles<sup>4</sup>, Donna Herr<sup>4</sup>, Lauren Davel<sup>4</sup>, Cara Bosco<sup>2</sup>, Khula South Africa Data Collection Team†<sup>4</sup>, Curtis Huttenhower<sup>5</sup> 1 2 3 4

- Nicolò Pini<sup>s,7</sup>, Daniel C. Alexanderª, Derek K. Jonesª, Steve C. R. Williams<sup>10</sup>, Dima Amso<sup>11</sup>, Melissa Gladstone<sup>12</sup>, William P. Fifer<sup>6,7</sup>, 5 6
	- Kirsten A. Donald<sup>3,13</sup>, Laurel J. Gabard-Durnam<sup>2</sup>‡, Vanja Klepac-Ceraj<sup>1</sup>‡,
- \*These authors contributed equally 7
- † Khula South African Data Collection Team: Layla Bradford, Simone Williams, Lauren Davel, Tembeka Mhlakwaphalwa, Bokang 8
- Methola, Khanyisa Nkubungu, Candice Knipe, Zamazimba Madi, Nwabisa Mlandu 9
- ‡ co-corresponding authors 10
- <sup>1</sup>Department of Biological Sciences, Wellesley College, Wellesley, MA, USA 11
- ²Department of Phychology, Northeastern University, Boston, MA, USA 12
- <sup>3</sup>Division of Medical Microbiology, University of Cape Town, Cape Town, Western Cape, ZAF 13
- ⁴Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, ZAF 14
- ⁵Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA 15
- ⁶Department of Psychiatry, Columbia University, Irving Medical Center, New York City, NY, USA 16
- ⁷Division of Developmental Neuroscience, New York State Psychiatric Institute, New York City, NY, USA 17
- ⁸Centre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom 18
- ⁹Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, Wales, United Kingdom 19
- <sup>10</sup>Department of Neuroimaging, King's College London, United Kingdom 20
- <sup>11</sup>Department of Psychology, Columbia University, New York City, NY, USA 21
- <sup>12</sup>Department of Women and Children's Health, Institute of Life Course and Medical Science, Alder Hey Children's NHS Foundation 22
- Trust, University of Liverpool, Liverpool, United Kingdom 23
- 13Neuroscience Institute, University of Cape Town, Cape Town, Western Cape, ZAF 24
- **Running title**: Infant gut microbiome and visual neurodevelopment 25
- **Keywords**: visual cortex development, metagenome, infant gut microbiome, visual-evoked potential, neuroplasticity 26

#### **ORCID numbers:** 27



## **Abstract** 38

- Infancy is a time of elevated neuroplasticity supporting rapid brain and sensory development. The gut 39
- microbiome, also undergoing extensive developmental changes in early life, may influence brain 40
- development through metabolism of neuroactive compounds. Here, we leverage longitudinal data from 41
- 194 infants across the first 18 months of life to show that microbial genes encoding enzymes play a key 42
- role in modulating early neuroplasticity are associated with visual cortical neurodevelopment, measured 43
- by the Visual-Evoked Potential (VEP). Neuroactive compounds included neurotransmitters GABA and 44
- glutamate, the amino acid tryptophan, and short-chain fatty acids involved in myelination, including 45
- acetate and butyrate. Microbial gene sets around 4 months of age were strongly associated with the VEP 46
- from around 9 to 14 months of age and showed more associations than concurrently measured gene 47
- sets, suggesting microbial metabolism in early life may affect subsequent neural plasticity and 48
- development. 49

## **Introduction** 50

- The gut microbiome in early life has potential long-term implications for brain and body health. One 51
- important way this influence can occur is through interactions with the central nervous system as a 52
- "microbial-gut-brain axis" ([1–](#page-11-0)[3\)](#page-11-1) The metabolic potential of the microorganisms that inhabit the gut vastly 53
- exceeds that of human cells alone, with microbial genes outnumbering host genes by a hundredfold [\(4\)](#page-11-2) 54
- In particular, gut microbes have the ability to metabolize and synthesize many neuroactive compounds 55
- [\(5\)](#page-11-3). However, the physiological relevance of this in humans has been difficult to quantify, particularly 56
- during initial neurological development in early life. 57
- Extensive work in preclinical models suggests that these neuroactive compounds can influence the brain 58
- through both direct and indirect pathways. For example, major neurotransmitters (e.g., glutamate, γ-59
- aminobutyric acid (GABA), serotonin, and dopamine) are readily synthesized and degraded by intestinal 60
- microbes and can enter circulation and pass the blood-brain barrier to influence central nervous function 61
- [\(6](#page-11-4)[–9\)](#page-12-0) Glutamatergic/GABA-ergic signaling is critical for balancing the brain's excitatory and inhibitory 62
- neurotransmission levels, and alterations in the bi-directional glutamatergic/GABA-ergic signaling 63
- between the gut microbiome and brain are implicated in several physical and mental health conditions 64
- [\(10](#page-12-1)[,11](#page-12-2)). Similarly, the gut and the microbiome are critical to the regulation of metabolism for the 65
- neurotransmitters serotonin and dopamine, particularly through the metabolism of dietary tryptophan 66
- [\(12](#page-12-3)). Moreover, short-chain fatty acids (SCFAs) produced by the gut microbiome may impact the brain 67
- directly by modulating neurotrophic factors, glial and microglial maturation and myelination, and 68
- neuroinflammation [\(13](#page-12-4)[,14](#page-12-5)). Other indirect pathways for gut microbial influence on the brain include vagus 69
- nerve stimulation, neuroendocrine modulation and immune system regulation [\(1\)](#page-11-0). 70
- Rapidly growing literature connects the metabolic potential of the gut microbiome and brain function in 71
- humans (reviewed in [7](#page-12-6)[,15](#page-12-7)[,16](#page-12-8)), but the overwhelming majority of this research is conducted in cohorts of 72
- adult participants. Importantly, both the gut microbiome and the brain undergo dramatic and rapid 73
- development over the first postnatal years ([17–](#page-12-9)[19](#page-12-10)) However, very little is currently known about how gut-74
- brain influences emerge or change during this critical window ([20](#page-12-11)–[22\)](#page-12-12). Interrogating this early co-75
- development in humans is, therefore, key to both understanding adaptive gut-brain function and behavior 76
- and to informing strategies to support it. Specifically, the visual cortex has been shown to be sensitive to 77
- gut microbiome modulations in adults ([23](#page-13-0)) and in rodents ([24\)](#page-13-1), yet the visual cortex undergoes its most 78
- rapid period of plasticity and maturation over infancy at the same time the microbiome changes most 79
- significantly ([25](#page-13-2)[–27](#page-13-3)). Visual cortical functional maturation can be robustly indexed via 80
- electroencephalography (EEG) with the Visual-Evoked Potential (VEP) response to visual stimuli from 81
- birth. The VEP is especially useful for indexing visual neurodevelopment as its morphology includes 82
- amplitude deflections as well as latencies to those deflections reflecting maturation of function and 83
- structure, respectively. 84

- Here, we investigated the longitudinal co-development of microbial metabolic potential quantified via 85
- genes encoding enzymes that metabolize neuroactive compounds and visual neurodevelopment as 86
- indexed by the VEP in a longitudinal community sample of 194 infants from Gugulethu in Cape Town, 87
- South Africa, recruited as part of the prospective longitudinal "Khula" Study ([28](#page-13-4)). Stool samples and EEG 88
- were each collected at up to 3 visits in the first 18 months of life. Shotgun metagenomic sequencing was 89
- used to obtain microbial gene sequences from infant stool samples. To index visual cortical functional 90
- development, latencies and peak amplitudes were extracted from each component of the VEP (i.e., first 91
- negative-going deflection, N1; first positive-going deflection, P1; and second negative-going deflection, 92
- N2), producing six VEP features of interest. We evaluated the concurrent association between microbial 93
- genes and VEP amplitudes and latencies, and we tested prospective influences of microbial genes from 94
- early visits on VEP changes at later visits. In this way, we were able to reveal the temporal dynamics of gut-brain co-development within individuals during this most critical window of plasticity in both systems. 95 96

#### **Methods and Materials** 97

**Cohort** 98

#### **Participants and Study Design** 99

- Infants were recruited from local community clinics in Gugulethu, an informal settlement in Cape Town, 100
- South Africa, as part of a prospective longitudinal study (most enrollments happened prenatally with 16% 101
- of infants enrolled shortly after birth; [28\)](#page-13-4). The first language for the majority of residents in this area is 102
- Xhosa. Study procedures were offered in English or Xhosa depending on the language preference of the 103
- mother. This study was approved by the relevant university Health Research Ethics Committees 104
- (University of Cape Town study number: 666/2021). Informed consent was collected from mothers on 105
- behalf of themself and their infants. Demographic information, including maternal place of birth, primary 106
- spoken language, maternal age at enrollment, maternal educational attainment, and maternal income, 107
- were collected at enrollment (see [Table 1\)](#page-18-0). 108
- Families were invited to participate in three in-lab study visits over their infant's first two years of life. At 109
- the first in-lab study visit (hereafter visit-1), occurring when infants were between approximately 2 months 110
- and 6 months of age, the following data were collected: the infants' age (in months), sex, infant 111
- electroencephalography (EEG), and infant stool samples. 112
- At the second study visit (hereafter visit-2), occurring when infants were between approximately 6 months 113
- and 12 months of age (age in months: M=8.60, SD=1.48, range=5.41-12.00) and at the third study visit 114
- (hereafter visit-3), occurring when infants were between approximately 12 months and 17 months of age 115
- (age in months: M=14.10, SD=1.04, range=12.10-17.00), infant EEG and stool samples were collected 116
- again. At visits in which infants were unable to complete both EEG and stool samples on the same day, 117
- EEG and stool samples were collected on different days. For concurrent time point analyses, infants with 118
- EEG and stool collected more than two months apart were excluded. Not all infants had EEG and 119
- microbiome data collected at all three time points or contributed usable data at all three-time points. 120
- All enrolled infants received a comprehensive medical exam at each visit, which included assessments of 121
- eye-related conditions. Several infants (n=3) were identified as having eye-related anomalies during the 122
- medical exam, and they were excluded from any further analyses. 123

## **EEG Processing** 124

#### **EEG Data Acquisition** 125

- Electroencephalography (EEG) data were acquired from infants while they were seated in their 126
- caregiver's lap in a dimly-lit, quiet room using a 128-channel high density HydroCel Geodesic Sensor Net 127
- (EGI, Eugene, OR), amplified with a NetAmps 400 high-input amplifier, and recorded via an Electrical 128

- Geodesics, Inc. (EGI, Eugene, OR) system with a 1000 Hz sampling rate. EEG data were online 129
- referenced to the vertex (channel Cz) through the EGI Netstation software. Impedances were kept below 130
- 100KΩ in accordance with the impedance capabilities of the high-impedance amplifiers. Geodesic 131
- Sensor Nets with modified tall pedestals designed for improving inclusion of infants with thick/curly/tall 132
- hair were used as needed across participants [\(29](#page-13-5)). Shea moisture leave-in castor oil conditioner was 133
- applied to hair across the scalp prior to net placement to improve both impedances and participant 134
- comfort [\(29](#page-13-5)). This leave-in conditioner contains insulating ingredients, so there is no risk of electrical 135
- bridging, and has not been found to disrupt the EEG signal during testing (unpublished data). 136
- Conditioning hair in this way allows for nets to lay closer to the scalp for curly/coily hair types and makes 137
- for more comfortable net removal at the end of testing. 138
- The Visual-Evoked Potential (VEP) taski was presented using Eprime 3.0 software (Psychology Software 139
- Tools, Pittsburgh, PA) on a Lenovo desktop computer with an external monitor 19.5 inches on the 140
- diagonal facing the infant (with monitor approximately 65 cm away from the infant). A standard phase-141
- reversal VEP was induced with a black and white checkerboard (1cm x 1 cm squares within the board) 142
- stimulus that alternated presentation (black squares became white, white squares became black) every 143
- 500 milliseconds for a total of 100 trials. Participant looking was monitored by video and by an assistant 144
- throughout data collection. If the participant looked away during the VEP task, the task was rerun. 145

#### **EEG Data Pre-Processing** 146

- VEP data were exported from native Netstation .mff format to .raw format and then pre-processed using 147
- the HAPPE+ER pipeline within the HAPPE v3.3 software, an automated open-source EEG processing 148
- software validated for infant data [\(30\)](#page-13-6). A subset of the 128 channels were selected for pre-processing that 149
- excluded the rim electrodes as these are typically artifact-laden (channels excluded from pre-processing 150
- included in Table S4). The HAPPE pre-processing pipeline was run with user-selected specifications 151
- outlined in Table S4. 152
- Pre-processed VEP data were considered usable and moved forward to VEP extraction if HAPPE pre-153
- processing ran successfully, at least 15 trials were retained following bad trial rejection, and at least one 154
- good channel was kept within the visual ROI. Note that channels marked bad during pre-processing had 155
- their data interpolated as part of standard preprocessing pipelines for ERPs [\(30\)](#page-13-6). Interpolated channels 156
- were included in analyses here as is typically done in developmental samples, and given the low overall 157
- rates of interpolation present (e.g., an average of between 4 to 5 of 5 possible good channels in the 158
- region of interest were retained at each visit time point). 159

## **Visual-Evoked Potentials (VEPs)** 160

- VEP waveforms were extracted and quantified using the HAPPE+ER v3.3 GenerateERPs script ([30\)](#page-13-6). 161
- Electrodes in the occipital region were selected as a region of interest (i.e., E70, E71, E75, E76, E83). 162
- The VEP waveform has three main components to be quantified: a negative N1 peak, a positive P1 peak, 163
- and a negative N2 peak. Due to normative maturation of the waveforms as infants age, one set of user-164
- specified windows for calculating component features was used for visit-1 and 2 and another was used 165
- for visit-3. For visits 1 and 2, the window for calculating features for the N1 component was 40-100 ms, 166
- 75-175 ms for the P1 component, and 100-325 ms for the N2 component. For visit-3, the window for 167
- calculating features for the N1 component was 35-80 ms, 75-130 ms for the P1 component, and 100-275 168
- ms for the N2 component. HAPPE+ER parameters used in extracting the ERPs are summarized in Table S5. 169 170
- To correct for the potential influence of earlier components on later components, corrected amplitudes 171
- and latencies were calculated and used in all analyses. Specifically, the P1 amplitude was corrected for 172
- the N1 amplitude (corrected P1 amplitude =  $P1 N1$  amplitude), the P1 latency was corrected for the N1 173
- 174
- latency (corrected P1 latency =  $P1 N1$  latency), the N2 amplitude was corrected for the P1 amplitude

- (corrected N2 amplitude = N2 P1 amplitude), and the N2 latency was corrected for the P1 latency (corrected N2 latency  $=$  N2 - P1 latency). 175 176
- All VEPs were visually inspected to ensure that the automatically extracted values were correct and were 177
- adjusted if observable peaks occurred outside the automated window bounds. Participants were 178
- considered to have failed this visual inspection and were subsequently removed from the data set if their 179
- VEP did not produce three discernible peaks. VEP waveforms of included participants by time point are 180
- included in [Figure 1](#page-22-0)E. 97 infants provided usable VEP data at visit-1, 130 infants provided usable VEP 181
- data at visit-2, and 131 infants provided usable VEP data at visit-3. For included participants, EEG data 182
- quality metrics are summarized in Table S6. T-tests for data quality metrics (i.e., number of trials 183
- collected, number of trials retained, number of channels retained in the ROI, Pearson's r for data pre- vs. 184
- post-wavelet thresholding at 5, 8, 12, and 20 Hz) were run between each visit combination (i.e., visit-1 vs. 185
- visit-2, visit-1 vs. visit-3, visit-2 vs. visit-3). For visits that differed in data quality, follow-up post hoc 186
- correlations were run for the data quality measure with each VEP feature at each visit in the T-test. In no 187
- case did the data quality metric relate to VEP features at multiple visits, making it highly unlikely the data quality difference contributed to results. 188 189
- 

## **Biospecimens and sequencing** 190

#### **Sample Collection** 191

- Stool samples (n=315) were collected in the clinic by the research assistant directly from the diaper, 192
- transferred to Zymo DNA/RNA ShieldTM Fecal collection Tubes (#R1101, Zymo Research Corp., Irvine, 193
- USA) and immediately frozen at −80 °C. Stool samples were not collected if the participant had taken 194
- antibiotics within the two weeks prior to sampling. 195

#### **DNA Extraction** 196

- DNA extraction was performed at Medical Microbiology, University of Cape Town, South Africa, from stool 197
- samples collected in DNA/RNA Shield™ Fecal collection tube using the Zymo Research Fecal DNA 198
- MiniPrep kit (# D4300, Zymo Research Corp., Irvine, USA) following manufacturer's protocol. To assess 199
- the extraction process's quality, ZymoBIOMICS® Microbial Community Standards (#D6300 and #D6310, 200
- Zymo Research Corp., Irvine, USA) were incorporated and subjected to the identical process as the stool 201
- samples. The DNA yield and purity were determined using the NanoDrop® ND −1000 (Nanodrop 202
- Technologies Inc. Wilmington, USA). 203

## **Sequencing** 204

- Shotgun metagenomic sequencing was performed on all samples at the Integrated Microbiome Research 205
- Resource (IMR, Dalhousie University, NS, Canada). A pooled library (max 96 samples per run) was 206
- prepared using the Illumina Nextera Flex Kit for MiSeq and NextSeq from 1 ng of each sample. Samples 207
- were then pooled onto a plate and sequenced on the Illumina NextSeq 2000 platform using 150+150 bp 208
- paired-end P3 cells, generating 24M million raw reads and 3.6 Gb of sequence per sample [\(31](#page-13-7)). 209

## **Statistics / computational analysis** 210

## **Age-Related Changes in VEP Features** 211

- To determine age-related changes in VEP features, six linear mixed models with each VEP feature as the 212
- outcome (i.e., N1 amplitude/latency, P1 amplitude/latency, N2 amplitude/latency) were run using the lme4 213
- package ([32\)](#page-13-8) in R with age in months as the predictor of interest and number of retained trials as a 214
- covariate. 215

#### **Metagenome processing** 216

- Raw metagenomic sequence reads  $(2.5 \times 107 \pm 1.4 \times 107 \text{ reads/sample})$  were processed using tools 217
- from the bioBakery as previously described [\(17](#page-12-9),[33](#page-13-9)). Briefly, KneadData v0.10.0 was used with default 218
- parameters to trim low-quality reads and remove human sequences (using reference database hg37). 219
- Next, MetaPhlAn v3.1.0 (using database mpa\_v31\_CHOCOPhlAn\_201901) was used with default 220
- parameters to map microbial marker genes to generate taxonomic profiles. Taxonomic profiles and raw 221
- reads were passed to HUMAnN v3.7 to generate stratified functional profiles. 222

#### **Microbial community analysis** 223

- Principal coordinates analysis was performed in the julia programming language [\(34](#page-13-10)) using the 224
- Microbiome.jl package [\(35\)](#page-13-11). Bray-Curtis dissimilarity (Distances.jl) was calculated across all pairs of 225
- samples, filtering for species-level classification. Classical multidimensional scaling was performed on the 226
- dissimilarity matrix (MultivariateStats.jl), and axes with negative eigenvalues were discarded. 227

#### **Feature Set Enrichment Analysis (FSEA)** 228

- Potentially neuroactive genesets were extracted from Supplementary Dataset 1 from [\(5](#page-11-3)). Gut-brain 229
- modules provide Kegg Orthologue IDs (KOs) [\(36,](#page-13-12)[37](#page-13-13)), which were mapped to UniRef90 IDs using the 230
- utility mapping file provided with HUMAnN v3.1 ([33\)](#page-13-9). For each stool/VEP pair, logistic regression (LR) 231
- was performed, linking the presence or absence of that UniRef in a sample with each VEP feature (i.e., 232
- N1, P1, and N2 latencies and amplitudes), controlling for the age at which the stool sample was 233
- collected, the number of retained VEP trials, and the difference in age between the stool collection and 234
- VEP measurement. For concurrently collected stool and VEP comparisons ([Figure 2\)](#page-22-1), participants whose 235
- stool collection and VEP measurements were more than two months apart were excluded. 236
- UniRef  $\sim$  vep + age\_months + n\_trials + age\_diff 237
- FSEA was performed on each geneset that had at least five members in each comparison group 238
- according to the procedure set out in Subramanian et. al. (2005) [\(38\)](#page-13-14). Briefly, enrichment scores (ES) are 239
- calculated based on the rank order of z-statistics from the LR for each UniRef. A permutation test was 240
- then performed where the ES for 5000 random samples of ranks of the same length as the gene set are 241
- calculated, and the pseudo-p value is the fraction of permutations where the permutation ES has a 242
- greater absolute value than the true ES. 243
- Benjamini-Hochberg FDR correction was performed separately on all concurrently tested geneset/VEP 244
- feature combinations and all longitudinal geneset/VEP feature combinations. Corrected p-values (q-245
- values) less than 0.2 were considered statistically significant. 246
- For longitudinal comparisons, all participants that had a stool sample collected at one visit and a VEP 247
- assessment at a subsequent visit were included (visit-1 stool  $\rightarrow$  visit-2 VEP, N = 84; v1  $\rightarrow$  v2, N = 76; v2 248
- $\rightarrow$  v3, N = 69). A total of 95 geneset/VEP features were significant when using an FDR-corrected p-value 249
- cutoff of q < 0.2. To ensure the robustness of these findings, we randomly permuted participant IDs 250
- between the stool and VEP assessments and repeated the analysis. Over 10 random permutations, a 251
- mean of 19.5 significant associations were identified, suggesting that FDR correction is correctly 252
- calibrating the false-positive rate. 253

## **Data and code availability** 254

- Code for initial processing of data and for analyses performed in this manuscript are available on github 255
- and archived on Zenodo ([39\)](#page-14-0). Input data will be archived on Dryad and downloadable via included scripts 256
- in analysis code upon publication. 257

## **Results** 258

#### **The brain and microbiome develop rapidly in the first months of life** 259

To investigate the co-development of the gut microbiome and visual neurodevelopment, we collected 260

- stool and the VEP in a longitudinal cohort of 194 children in South Africa during the first 18 months of life 261
- [\(Figure 1A](#page-22-0), B, [Table 1;](#page-18-0) visit-1, N = 119, age  $3.6 \pm 0.7$  months, visit-2, N = 144, age  $8.7 \pm 1.4$  months, 262
- visit-3, N = 130, age  $14.2 \pm 1.0$  months). As expected for children at this age [\(40–](#page-14-1)[42\)](#page-14-2), microbial 263
- composition was developmentally dependent, with the first principal coordinate axis for both taxonomic 264
- profiles [\(Figure 1C](#page-22-0); variance explained = 15.1%; R = −0.50) and functional profiles ([Figure 1](#page-22-0)D; variance 265
- explained = 12.9%; R = −0.57) driven strongly by the age of the participant at the time of collection. 266
- Similarly, both amplitude and latency VEP features were strongly correlated with age, as expected 267
- [\(18](#page-12-13)[,41](#page-14-3)) That is, as infants got older, N1 amplitude became more negative (N1: b=-0.07, p<.05), corrected 268
- P1 amplitude became smaller (P1: b=-0.50, p<.05), corrected N2 amplitude became smaller (N2: b=0.52, 269
- p<.05), and all latencies became shorter (N1: b=-0.79, p<.05; P1: b=-1.21, p<.05; N2: b=-4.10, p<.05) [\(Figure 1E](#page-22-0)). 270 271
- **Microbial genes with neuroactive potential are associated with concurrently measured visual** 272 273

## **development**

- To test whether microbial metabolic potential was related to early life brain activity, we performed feature 274
- set enrichment analysis (FSEA) using previously-defined groups of potentially neuroactive microbial 275
- genes and the concurrently measured VEP amplitude and latency features [\(17,](#page-12-9)[5\)](#page-11-3). For each gene set that 276
- had at least 5 genes represented in a given comparison group, logistic regression was performed using 277
- VEP features as predictors and the presence or absence of each microbial gene in the metagenome as 278
- the response to determine concurrent associations (see Methods). Z statistics for in-set genes were 279
- compared to all genes using a permutation test to determine significance of the associations as 280
- described in Subramanian et. al., (2005) ([38\)](#page-13-14). 281
- Of the 35 genesets assessed, 19 had sufficient representation to test, and of those, 18 were significantly associated with at least one EEG feature during at least one visit within the 18-month window, after correcting for false discovery rate (Benjamini-Hochberg, q < 0.2; [Figure 2,](#page-22-1) Table S2). Microbial genes involved in synthesis or degradation of molecules with neuroactive potential across all categories 282 283 284 285
- considered (i.e., neurotransmitters, amino acid metabolism, SCFAs, other) were associated with both 286
- VEP amplitudes and latencies at each visit, demonstrating widespread associations between early life gut 287
- microbiome and visual cortex neurodevelopment. The number of these associations increased over time 288
- (visit-1 had 6 associations, visit-2 had 24, and visit-3 had 37). To differentiate whether this cross-sectional 289
- finding indicated the early microbiome (~4 months) was sparsely related to visual cortical development at 290
- 4 months only or more broadly at all subsequent time points, longitudinal analyses were performed 291
- (results below). 292
- Specifically, across the gene sets involved in neurotransmitter synthesis and degradation, glutamate 293
- synthesis/degradation and GABA synthesis showed associations with all VEP features, primarily at the 294
- 2nd and 3rd visit (mean ages 8.6 and 14.1 months, respectively; Table S2). Gene sets involved in 295
- tryptophan metabolism and associated pathways (i.e., quinolinic acid) were also strongly concurrently 296
- related to VEP development. Specifically, tryptophan metabolism genes were associated with VEP 297
- latencies just after each VEP component showed its greatest window of developmental change 298
- (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2, and N2 at visit-3. 299 300
- Several short-chain fatty acid (SCFA)-metabolizing gene sets were also found to have multiple 301
- associations with VEP features. Specifically, acetate synthesis was strongly associated with almost all 302
- VEP features (Table S2). Butyrate synthesis was associated with P1 and N2 amplitudes and latencies 303

- around the end of the first year of life (visits 2 and 3), when the visual cortex is most actively undergoing 304
- myelination. Lastly, propionate synthesis/degradation was significantly associated with VEP latencies at 305
- every visit over the 18-month window (N1 at visits 1 and 2, and both P1 and N2 at visit-3). These SCFA 306
- metabolizing genes showed almost double the concurrent associations with VEP latencies than 307
- amplitudes (11 associations with latencies, 6 associations with amplitudes). 308
- Finally, within the remaining gene sets tested, we observed robust associations in particular between 309
- menaquinone (Vitamin K2) gene sets and the VEP features over this infancy window. This is an expected 310
- relationship, as vitamin K2 specifically is posited to promote healthy vision, both outside of the brain 311
- through effects on the retina, and within the brain where it can protect neural circuits from oxidative stress 312
- [\(43](#page-14-4)). 313
- Notably, across significant gene set associations with VEP features, the P1 and N2 component 314
- amplitudes and latencies were consistently the most sensitive to these microbial gene sets. Both P1 and 315
- N2 components are known to show the most dramatic changes with development during the first year of 316
- life ([44\)](#page-14-5) and may best reflect underlying visual learning and plasticity at this stage (Table S1). 317
- Microbial metabolic potential predicts future brain development in infancy Given that differences in 318
- metabolic potential of the early life microbiome may exert their effects over time, we sought to determine 319
- whether microbial genes at early time points were associated with subsequent VEP development. To 320
- investigate this, we performed FSEA on stool samples collected at visit-1 with visit-2 VEP (age at stool 321
- collection =  $3.6 \pm 0.8$  months, age at VEP =  $8.6 \pm 1.5$  months) or visit-3 VEP (age at stool collection =  $3.7$ 322
- $\pm$  0.7 months, age at VEP = 14.1  $\pm$  1.1 months), as well as visit-2 stool samples with visit-3 VEP (age at 323
- stool collection =  $8.9 \pm 1.5$  months, age at VEP =  $14.3 \pm 1.0$  months; Table S3) ([Figure 3A](#page-22-2)). 324
- All gene sets except those involved in the synthesis of 3,4-dihydroxyphenylacetic acid (DOPAC), a 325
- metabolite of dopamine, that had a significant hit with concurrently measured VEP were also significantly 326
- associated with at least one future VEP feature ([Figure 3](#page-22-2)B, Tables 2-5). Notably, the quantity of those 327
- associations increased substantially for all longitudinal comparisons compared to concurrent 328
- comparisons. For example, only 6 visit-1 microbial gene sets were associated with visit-1 VEP, and each 329
- of those was only associated with a single concurrently measured VEP feature. By contrast, these 330
- longitudinal analyses revealed that visit-1 microbial gene sets show a much richer pattern of associations 331
- with future VEP feature development. Specifically, 13 visit-1 gene sets were associated with visit-2 VEP 332
- features, and 11 were associated with visit-3 VEP features, the majority (9/13 for visit-2, 8/11 for visit-3) 333
- were associated with at least 2 VEP features, and nearly half (6/13 for visit-2, 5/11 for visit-3) were 334
- associated with more than 2 future VEP features. 335
- Longitudinally, the early microbiome (visit-1) was related to VEP features at visit-2 and visit-3 fairly evenly 336
- (12/28 visit-1 microbiome associations to visit-3 VEP latencies, 15/30 associations to visit-3 amplitudes), 337
- suggesting early microbiome metabolism in the first 6 months of life is associated with visual 338
- neurodevelopment over the next year. Microbiome metabolism from visit-2 was associated with similar 339
- numbers of visit-3 VEP features as visit-1 microbiome (17 visit-3 latency features, 18 visit-3 amplitude 340
- features), suggesting continued co-development of these systems over the first postnatal year. 341
- Neurotransmitters GABA and glutamate, tryptophan metabolism (tryptophan and quinolinic acid), SCFAs 342
- including acetate, butyrate, and propionate, as well as menaquinone (Vitamin K2) were again all 343
- significantly associated with multiple VEP features across multiple longitudinal comparisons. 344
- Importantly, the nature and identity of the longitudinal associations varied over development for many 345
- gene sets, indicating temporal specificity to these associations. With respect to the neurotransmitter-346
- related pathways, amongst the associations between GABA synthesis genes and future VEP features, 347
- GABA genes specifically from visit-1 showed the greatest number of associations with future VEP 348
- features (5/6 GABA associations) at visits 2 and 3 equally, and the majority of these associations were 349

- VEP amplitudes (reflecting development of neurotransmission including excitatory/inhibitory balance). To 350
- a lesser extent, glutamate metabolism genes followed a similar temporal pattern (8/13 glutamate 351
- associations involved visit-1 genes) but did not relate to amplitudes or latencies differentially like GABA. 352
- This pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate 353
- dynamics, especially GABA, are most relevant for changes to visual cortex function over the following year. 354 355
- Tryptophan-related pathway genes (responsible for generating serotonin, amongst other products) from 356
- visit-1 were also responsible for the majority of associations with future VEP features (tryptophan: 6/8 357
- associations; quinolinic acid: 6/9 associations). In contrast to GABA but similar to glutamate, tryptophan-358
- related gene associations were largely shorter-term associations with VEP features at the visit 359
- immediately following gene set measurement (approximately 5 months later; 12/17 associations), 360
- indicating dynamic co-development over the first 18 months of life. Across neurotransmitter-related gene 361
- set associations (GABA, glutamate, tryptophan/serotonin), there was thus a clear pattern whereby early 362
- (~4 months old) microbiome gene sets showed the largest number of associations with subsequent VEP 363
- feature development. 364
- SCFAs showed a different developmental pattern of associations with future VEP features. Specifically, 365
- propionate and butyrate metabolism genes from both visit-1 and visit-2 showed associations with future 366
- VEP features, but here the effects were almost entirely observed for VEP features at visit-3 (10/10 367
- propionate and 7/8 butyrate associations). Moreover, acetate and butyrate metabolism genes were 368
- doubly associated with future VEP latencies compared to amplitude features. 369
- Finally, menaquinone (Vitamin K2) metabolism genes followed a similar pattern to the SCFAs in that 370
- genes from visit-1 and visit-2 were largely associated with future VEP features at visit-3 (8/9 371
- menaquinone associations). This indicates persistent associations of this early microbiome gene set with 372
- individual differences in VEP features early in the second year of life. 373
- It is possible that extrinsic factors related to development mutually influence both the gut microbiome and 374
- neural development, though we additionally tested whether VEP features were associated with microbial 375
- metabolism at a future visit, and found substantially fewer associations (29 total associations, compared 376
- with 95 when analyzing early stool samples with future VEP). While this does not prove a causal 377
- relationship, it is consistent with the hypothesis that microbial metabolism influences brain development. 378

#### **Discussion** 379

- The past decade has seen a remarkable growth in our understanding of the relationships between the 380
- developmental changes of the gut microbiome and the brain. However, a great deal of that investigation 381
- has focused on adult populations or neuropsychiatric disorders, limiting the potential to explain how these 382
- associations emerge during early development. Here, we address this key open question by leveraging a 383
- rich longitudinal dataset over the first year of life, which is the time of greatest developmental change for 384
- both the microbiome and brain given the unfolding of foundational sensory neurodevelopment. Our data 385
- revealed that microbial genes involved in the metabolism of neuroactive molecules are associated with 386
- concurrent and subsequent visual cortical neurodevelopment. These pathways included those for the 387
- neurotransmitters GABA and glutamate, the amino acid tryptophan, and short-chain fatty acids involved 388
- in myelination, including acetate and butyrate. 389
- Specifically, we have shown a robust, prospective relationship between microbial genes involved in the 390
- metabolism of neuroactive compounds and the development of visual cortical function as measured by 391
- the VEP electrophysiological response. We found that microbial metabolism is more strongly associated 392
- with future measures of the VEP than those collected concurrently. While not dispositive, this would be 393
- the predicted outcome if microbial genes are causally influencing brain development. As additional 394

evidence for this interpretation, we did not observe the same rich set of associations in the converse 395

- analyses examining whether VEP related to future microbiome properties. Microbial metabolism within 396
- the first 6 months shows the most associations with subsequent visual neurodevelopment, suggesting 397
- the early postnatal microbiome may play a particularly important role in the co-development of these systems. This interpretation is also supported by prior research showing that associations of the 398 399
- 
- microbiome with behavioral readouts of neurocognition are stronger prospectively than concurrently ([45\)](#page-14-6). Moreover, specific associations between gene sets and VEP features showed temporal specificity within 400 401
- the 18-month developmental window assessed, suggesting that the impact of early microbial metabolism 402
- on the brain is developmentally dependent. 403
- Notably, the gene sets most highly associated with visual functional neurodevelopment over infancy are 404
- for the metabolism of molecules with known links to developmental neuroplasticity ([46](#page-14-7)[–48\)](#page-14-8). Specifically, 405
- we observed associations for gene sets related to glutamate and GABA, neurotransmitters that are 406
- central to regulating excitatory/inhibitory (E/I) cortical balance. Developmental changes in E/I balance 407
- modulate the degree of neuroplasticity in the mammalian cortex, including regulating the start and 408
- progression of critical period neuroplasticity mechanisms in the visual cortex [\(47](#page-14-9)[,46](#page-14-7)[,49](#page-14-10),[50](#page-14-11)). Our observed 409
- pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate 410
- dynamics, especially GABA, are most relevant for changes to visual cortex function over the following year. Gut production of GABA may influence cortical GABA levels via active transport from bloodstream 411 412
- to brain [\(51](#page-14-12)–[53](#page-14-13)). Recent evidence suggests gut-derived glutamate may also influence brain levels and 413
- function ([8–](#page-12-14)[10](#page-12-1)) and can operate via indirect mechanisms (either transformation into GABA or via 414
- regulating glutamate levels in the bloodstream that impact glutamate transfer from brain to bloodstream). 415
- Tryptophan related pathway genes were also identified here that are responsible for generating serotonin 416
- as well as other neuroactive molecules such as kynurenic acid (an SMDAR antagonist) [\(12](#page-12-3)). Both 417
- serotonin and kynurenic acid are implicated in early neuroplasticity and neurotransmitter regulation, and 418
- serotonin has potent effects for visual cortex plasticity in particular ([54,](#page-14-14)[55\)](#page-15-0). While quinolinic acid is part of 419
- the kynurenine pathway and is a neurotoxin that can cause neuronal dysfunction, it may also play a role 420
- in glutamate uptake in the brain ([56,](#page-15-1)[57\)](#page-15-2). Specifically, tryptophan metabolism genes were associated with 421
- VEP latencies just after each VEP component showed its greatest window of developmental change 422
- (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2, 423
- and N2 at visit-3. This pathway may thus relate to processes stabilizing the neural circuitry (i.e. 424
- downregulating neuroplasticity) underlying each VEP component, an account consistent with recently 425
- observed effects of serotonin within the visual cortex in rodents [\(58](#page-15-3)). Importantly, nearly all of the body's 426
- serotonin is produced in the gut by enterochromaffin cells, and this biosynthesis is regulated by microbes 427
- [\(59](#page-15-4)[,60](#page-15-5)), making this pathway an especially promising candidate intervention target for further research in development. 428 429
- We further found that gene sets for short-chain fatty acids important in downregulating neuroinflammation 430
- and promoting myelination within the brain were robustly related to visual neurodevelopment. Myelination is important for down-regulating plasticity in neural circuitry over development by stabilizing and 431 432
- protecting circuits that have been shaped by early experience ([61\)](#page-15-6). Specifically, we observed 433
- associations between acetate, butyrate, and proprionate genes with VEP development. Acetate is a 434
- critical component required for the increased lipid synthesis that happens during postnatal myelination in 435
- the brain ([62\)](#page-15-7). Circulating butyrate also increases myelination [\(63](#page-15-8)), and though propionate's relation to 436
- myelinating oligodendrocytes remains unclear, it is known to protect myelinating Schwann cells outside of 437
- the brain from oxidative stress [\(64](#page-15-9)). Acetate, butyrate, and propionate are all also widely regarded as 438
- neuroprotective by promoting healthy microglial development and downregulating neuroinflammation that 439
- interferes with myelination ([65\)](#page-15-10). VEP latency features reflect myelination [\(50](#page-14-11),[66](#page-15-11),[67\)](#page-15-12), and accordingly, 440
- these SCFAs showed more associations with VEP latency features prospectively, especially VEP latency 441

features in vsit 3. This pattern of results is consistent with these SCFA roles' in myelination occurring over 442

the second half of the developmental window studied. SCFAs including acetate, butyrate, and propionate 443

can pass the blood-brain barrier to directly influence myelination-related processes within the brain. 444

Taken together, the pattern of results across GABA, glutamate, tryptophan, and SCFA gene sets 445

suggests early postnatal microbiome-derived metabolites relate to key neuroplasticity regulation 446

processes within the cortex. 447

Our study is a substantial advancement over prior work on the microbial-gut-brain axis in early life due to the sequencing method, the large number of participants, the longitudinal study design, and the inclusion of participants from a previously under-represented region of the world. The use of shotgun metagenomic sequencing enables direct interrogation of microbial metabolic potential. Prior research primarily used amplicon (16S rRNA gene) sequencing, which enables lower-resolution taxonomic identification and is restricted to inferring metabolic potential based on taxonomy. Moreover, while several studies in infancy have inferred gut-brain associations by linking microbiome measures to subsequent neurodevelopmental measures using behavioral assessments (e.g., Bayley Scales of Infant Development), noting associations with visually-mediated cognition [\(45\)](#page-14-6), this study assessed the development of the visual cortex directly using the VEP. The VEP is advantageous because features reflect largely neurotransmission-related (via amplitudes) or structural (i.e., myelination, via latencies) changes over this developmental window, facilitating some specificity in the observed associations. Moreover, the VEP can be indexed with fidelity from birth, providing a continuous measure of visual cortical function across the study age-range. Additionally, this study involved a large number of participants (194) contributing dense longitudinal data, with up to three time points, all taken in the first 18 months of an infant's life. While prior work focused on single time point measures of microbiome and neurodevelopment [\(68](#page-15-13)), longitudinal associations allowed us to investigate the changing relation between gut microbial metabolism and the development of visual neurocircuitry over time. 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465

One limitation of this study is the fact that we are only able to observe the genomic composition of the microbiome, rather than the concentration of metabolites themselves. This prevents us from determining the concentration of these molecules in the gastrointestinal tract, blood, and brain, as the abundance of these genes does not provide information about their activity, their interactions with other metabolic pathways (including those of the host), or absorption by colonic epithelial cells. Moreover, the relationship between gene abundance and molecule concentration may be counterintuitive, since the relationship between degradation and synthesis of metabolites occurs both at the individual organism level and at the community level. For example, genes for breaking down a molecule may be prevalent if that molecule is at high concentrations, or the molecules may be rapidly degraded by other members of the community the moment they are produced. Furthermore, it may be that the relation between metabolite and brain development remains stable over time, but the relation between molecules and microbial selection changes at different stages of life. Addressing these limitations in humans is challenging, even if looking at stool metabolites, because overall exposure throughout the gastrointestinal tract is not necessarily reflected in the final concentration of those molecules in stool. Therefore, metabolites from blood plasma could provide more accurate systemic concentrations of molecules, but challenges remain on how to interpret them in humans ([69](#page-15-14)[,70\)](#page-16-0). 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481

Given that the VEP is evolutionarily conserved in mammals and can be accurately measured during development, the hypotheses generated in humans in this study are readily testable mechanistically using in vivo models in future research. For example, VEP could be assessed in germ-free or definedmicrobiome animals (Wymore Brand et al. 2015; Kennedy, King, and Baldridge 2018) and may be supplemented with specific molecules such as SCFAs, or colonized with microbial species lacking or providing specific metabolic pathways. Furthermore, molecule concentrations in tissues from the gut to the brain can be directly assessed in these models. Uncovering relations between microbial metabolism 482 483 484 485 486 487 488

- and specific molecules may also generate hypotheses that can be confirmed in human data. This study, 489
- therefore, provides a foundation for deep investigation of the link between the human gut microbiome and 490
- brain development. 491

### **Acknowledgments** 492

- We would like to extend our thanks to all the caregivers and their infants who generously provided their 493
- time and samples for this study. We are also grateful to the dedicated nurses and researchers who 494
- recruited participants and collected data, ensuring the success of this project. This research was 495
- supported by the Wellcome LEAP 1kD program. 496

#### **CRediT** 497

- Conceptualization: KSB, ETM, KAD, LJGD, VKC 498
- Data curation: KSB, ETM, GFB, FP, SM, MRZ, MM, DH 499
- Formal analysis: KSB, ETM 500
- Funding acquisition: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC 501
- Investigation: KSB, ETM, GFB, SM, MRZ, MM, DH 502
- Methodology: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC 503
- Project administration: MRZ, MM, DH, LJGD, VKC 504
- Software: KSB, ETM, GFB, CH, LJGD 505
- Resources: SM, AS, FP, MRZ, MM, LD, CB, Khula, KAD, VKC 506
- Supervision: KSB, LJGD, VKC 507
- Validation: KSB, ETM 508
- Visualization: KSB, ETM 509
- Writing original draft: KSB, ETM, LJGD, VKC 510
- Writing review & editing: KSB, ETM, CH, NP, KAD 511

#### **Author correspondence** 512



## **Bibliography** 518

- <span id="page-11-0"></span>1. Rhee S H, Pothoulakis C, Mayer E A (2009): Principles and Clinical Implications of the Brain-Gut-Enteric Microbiota Axis. *Nature Reviews Gastroenterology & Hepatology* 6: 306–314. 519 520
- 2. Collins S M, Surette M, Bercik P (2012): The Interplay between the Intestinal Microbiota and the Brain. *Nature Reviews Microbiology* 10: 735–742. 521 522
- <span id="page-11-1"></span>3. Brett B E, Weerth C de (2019): The Microbiota–Gut–Brain Axis: A Promising Avenue to Foster Healthy Developmental Outcomes. *Developmental Psychobiology* 61: 772–782. 523 524
- <span id="page-11-2"></span>4. Gilbert J A, Blaser M J, Caporaso J G, Jansson J K, Lynch S V, Knight R (2018): Current Understanding of the Human Microbiome. *Nature Medicine* 24: 392–400. 525 526
- <span id="page-11-3"></span>5. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar E F, Wang J, Tito R Y, *et al.* (2019): The Neuroactive Potential of the Human Gut Microbiota in Quality of Life and Depression. *Nature microbiology* 4: 623– 632. 527 528 529
- <span id="page-11-4"></span>6. Janik R, Thomason L A M, Stanisz A M, Forsythe P, Bienenstock J, Stanisz G J (2016): Magnetic Resonance Spectroscopy Reveals Oral Lactobacillus Promotion of Increases in Brain GABA, N-acetyl Aspartate and Glutamate. *NeuroImage* 125: 988–995. 530 531 532

- <span id="page-12-6"></span>7. Ahmed H, Leyrolle Q, Koistinen V, Kärkkäinen O, Layé S, Delzenne N, Hanhineva K (2022): Microbiota-Derived Metabolites as Drivers of Gut–Brain Communication. *Gut Microbes* 14: 2102878– 2102879. 533 534 535
- <span id="page-12-14"></span>8. Matsumoto M, Kibe R, Ooga T, Aiba Y, Sawaki E, Koga Y, Benno Y (2013): Cerebral Low-Molecular Metabolites Influenced by Intestinal Microbiota: A Pilot Study. *Frontiers in Systems Neuroscience* 7: 9–10. 536 537 538
- <span id="page-12-0"></span>9. Kawase T, Nagasawa M, Ikeda H, Yasuo S, Koga Y, Furuse M (2017): Gut Microbiota of Mice Putatively Modifies Amino Acid Metabolism in the Host Brain. *The British Journal of Nutrition* 117: 775–783. 539 540 541
- <span id="page-12-1"></span>10. Filpa V, Moro E, Protasoni M, Crema F, Frigo G, Giaroni C (2016): Role of Glutamatergic Neurotransmission in the Enteric Nervous System and Brain-Gut Axis in Health and Disease. *Neuropharmacology* 111: 14–33. 542 543 544
- <span id="page-12-2"></span>11. Baj A, Moro E, Bistoletti M, Orlandi V, Crema F, Giaroni C (2019): Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. *International Journal of Molecular Sciences* 20: 1482–1483. 545 546
- <span id="page-12-3"></span>12. Agus A, Planchais J, Sokol H (2018): Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. *Cell Host & Microbe* 23: 716–724. 547 548
- <span id="page-12-4"></span>13. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019): The Role of Short-Chain Fatty Acids in Microbiota–Gut–Brain Communication. *Nature Reviews Gastroenterology & Hepatology* 16: 461– 478. 549 550 551
- <span id="page-12-5"></span>14. Erny D, Dokalis N, Mezö C, Castoldi A, Mossad O, Staszewski O, *et al.* (2021): Microbiota-Derived Acetate Enables the Metabolic Fitness of the Brain Innate Immune System during Health and Disease. *Cell Metabolism* 33: 2260–2276. 552 553 554
- <span id="page-12-7"></span>15. Parker A, Fonseca S, Carding S R (2019): Gut Microbes and Metabolites as Modulators of Blood-Brain Barrier Integrity and Brain Health. *Gut Microbes* 11: 135–157. 555 556
- <span id="page-12-8"></span>16. Aburto M R, Cryan J F (2024): Gastrointestinal and Brain Barriers: Unlocking Gates of Communication across the Microbiota–Gut–Brain Axis. *Nature Reviews Gastroenterology & Hepatology* 21: 222–247. 557 558 559
- <span id="page-12-9"></span>17. Bonham K, Bottino G F, McCann S H, Beauchemin J, Weisse E, Barry F, *et al.* (2023): Gut-Resident Microorganisms and Their Genes Are Associated with Cognition and Neuroanatomy in Children. *Science Advances* 9: eadi497. 560 561 562
- <span id="page-12-13"></span>18. Lippé S, Roy M-S, Perchet C, Lassonde M (2007): Electrophysiological Markers of Visuocortical Development. *Cerebral Cortex* 17: 100–107. 563 564
- <span id="page-12-10"></span>19. Dean D C, O'Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, Walker L, *et al.* (2014): Modeling Healthy Male White Matter and Myelin Development: 3 through 60 ~ Months of Age. *NeuroImage* 84: 742–752. 565 566 567
- <span id="page-12-11"></span>20. Ahrens A P, Hyötyläinen T, Petrone J R, Igelström K, George C D, Garrett T J, *et al.* (2024): Infant Microbes and Metabolites Point to Childhood Neurodevelopmental Disorders. *Cell* 187: 1853–1873. 568 569
- 21. Meyer K, Lulla A, Debroy K, Shikany J M, Yaffe K, Meirelles O, Launer L J (2022): Association of the Gut Microbiota With Cognitive Function in Midlife. *JAMA Network Open* 5: e2143941. 570 571
- <span id="page-12-12"></span>22. Callaghan B L, Fields A, Gee D G, Gabard-Durnam L, Caldera C, Humphreys K L, *et al.* (2020): Mind and Gut: Associations between Mood and Gastrointestinal Distress in Children Exposed to Adversity. *Development and Psychopathology* 32: 309–328. 572 573 574

- <span id="page-13-0"></span>23. Canipe L G, Sioda M, Cheatham C L (2021): Diversity of the Gut-Microbiome Related to Cognitive Behavioral Outcomes in Healthy Older Adults. *Archives of Gerontology and Geriatrics* 96: 104464– 104465. 575 576 577
- <span id="page-13-1"></span>24. Lupori L, Cornuti S, Mazziotti R, Borghi E, Ottaviano E, Cas M D, *et al.* (2022): The Gut Microbiota of Environmentally Enriched Mice Regulates Visual Cortical Plasticity. *Cell Reports* 38. https://doi.org/ [10.1016/j.celrep.2021.110212](https://doi.org/10.1016/j.celrep.2021.110212) 578 579 580
- <span id="page-13-2"></span>25. Deen B, Richardson H, Dilks D D, Takahashi A, Keil B, Wald L L, *et al.* (2017): Organization of High-Level Visual Cortex in Human Infants. *Nature Communications* 8: 13995–13996. 581 582
- 26. Ellis C T, Yates T S, Skalaban L J, Bejjanki V R, Arcaro M J, Turk-Browne N B (2021): Retinotopic Organization of Visual Cortex in Human Infants. *Neuron* 109: 2616–2626. 583 584
- <span id="page-13-3"></span>27. Kiorpes L (2015): Visual Development in Primates: Neural Mechanisms and Critical Periods. *Developmental Neurobiology* 75: 1080–1090. 585 586
- <span id="page-13-4"></span>28. Zieff M R, Miles M, Mbale E, Eastman E, Ginnell L, Williams S C R, *et al.* (2024): Characterizing Developing Executive Functions in the First 1000 Days in South Africa and Malawi: The Khula Study. *Wellcome Open Research* 9: 157–158. 587 588 589
- <span id="page-13-5"></span>29. Mlandu N, McCormick S A, Davel L, Zieff M R, Bradford L, Herr D, *et al.* (2024): Evaluating a Novel High-Density EEG Sensor Net Structure for Improving Inclusivity in Infants with Curly or Tightly Coiled Hair. *Developmental Cognitive Neuroscience* 67: 101396–101397. 590 591 592
- <span id="page-13-6"></span>30. Monachino A D, Lopez K L, Pierce L J, Gabard-Durnam L J (2022): The HAPPE plus Event-Related (HAPPE+ER) Software: A Standardized Preprocessing Pipeline for Event-Related Potential Analyses. *Modeling Neural Development* 57: 101140–101141. 593 594 595
- <span id="page-13-7"></span>31. Comeau A M, Filloramo G V (2023): Preparing Multiplexed WGS/MetaG Libraries with the Illumina DNA Prep Kit for the Illumina NextSeq or MiSeq. Retrieved August 14, 2024, from [https://www.](https://www.protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w) [protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w](https://www.protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w) 596 597 598
- <span id="page-13-8"></span>32. Bates D, Mächler M, Bolker B, Walker S (2015): Fitting Linear Mixed-Effects Models Using Lme4. *Journal of Statistical Software* 67: 1–48. 599 600
- <span id="page-13-9"></span>33. Beghini F, McIver L J, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, *et al.* (2021): Integrating Taxonomic, Functional, and Strain-Level Profiling of Diverse Microbial Communities with bioBakery 3. *Elife* 10. https://doi.org/[10.7554/eLife.65088](https://doi.org/10.7554/eLife.65088) 601 602 603
- <span id="page-13-10"></span>34. Bezanson J, Edelman A, Karpinski S, Shah V B (2017): Julia: A Fresh Approach to Numerical Computing. *Siam Review* 59: 65–98. 604 605
- <span id="page-13-11"></span>35. Bonham K, Kayisire A, Luo A, Klepac-Ceraj V (2021): Microbiome.Jl and BiobakeryUtils.Jl - Julia Packages for Working with Microbial Community Data. *Journal of Open Source Software* 6: 3876– 3877. 606 607 608
- <span id="page-13-12"></span>36. Suzek B E, Huang H, McGarvey P, Mazumder R, Wu C H (2007): UniRef: Comprehensive and Non-Redundant UniProt Reference Clusters. *Bioinformatics* 23: 1282–1288. 609 610
- <span id="page-13-13"></span>37. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004): The KEGG Resource for Deciphering the Genome. *Nucleic Acids Research* 32: D277–D280. 611 612
- <span id="page-13-14"></span>38. Subramanian A, Tamayo P, Mootha V K, Mukherjee S, Ebert B L, Gillette M A, *et al.* (2005): Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression 613 614
- Profiles. *Proceedings of the National Academy of Sciences* 102: 15545–15550. 615

- <span id="page-14-0"></span>39. Bonham K (2024, September 1): Klepac-Ceraj-Lab/EEGMicrobiome: Initial Submission. https://doi. org[/10.5281/zenodo.13625448](https://doi.org/10.5281/zenodo.13625448) 616 617
- <span id="page-14-1"></span>40. Koenig J E, Spor A, Scalfone N, Fricker A D, Stombaugh J, Knight R, *et al.* (2011): Succession of Microbial Consortia in the Developing Infant Gut Microbiome. *Proceedings of the National Academy of Sciences of the United States of America* 4578–4585. 618 619 620
- <span id="page-14-3"></span>41. Yassour M, Vatanen T, Siljander H, Hämäläinen A-M, Härkönen T, Ryhänen S J, *et al.* (2016): Natural History of the Infant Gut Microbiome and Impact of Antibiotic Treatment on Bacterial Strain Diversity and Stability. *Science Translational Medicine* 8: 343–344. 621 622 623
- <span id="page-14-2"></span>42. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, *et al.* (2015): Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell host & microbe* 17: 690– 703. 624 625 626
- <span id="page-14-4"></span>43. Li J, Lin J C, Wang H, Peterson J W, Furie B C, Furie B, *et al.* (2003): Novel Role of Vitamin K in Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons. *Journal of Neuroscience* 23: 5816–5826. 627 628 629
- <span id="page-14-5"></span>44. Lippe S, Kovacevic N, McIntosh R (2009): Differential Maturation of Brain Signal Complexity in the Human Auditory and Visual System. *Frontiers in Human Neuroscience* 3. https://doi.org/[10.3389/](https://doi.org/10.3389/neuro.09.048.2009) [neuro.09.048.2009](https://doi.org/10.3389/neuro.09.048.2009) 630 631 632
- <span id="page-14-6"></span>45. Carlson A L, Xia K, Azcarate-Peril M A, Goldman B D, Ahn M, Styner M A, *et al.* (2018): Infant Gut Microbiome Associated With Cognitive~Development. *Biological Psychiatry* 83: 148–159. 633 634
- <span id="page-14-7"></span>46. Fagiolini M, Hensch T K (2000): Inhibitory Threshold for Critical-Period Activation in Primary Visual Cortex. *Nature* 404: 183–186. 635 636
- <span id="page-14-9"></span>47. Hensch T K, Fagiolini M, Mataga N, Stryker M P, Baekkeskov S, Kash S F (1998): Local GABA Circuit Control of Experience-Dependent Plasticity in Developing Visual Cortex. *Science* 282: 1504–1508. 637 638
- <span id="page-14-8"></span>48. Takesian A E, Bogart L J, Lichtman J W, Hensch T K (2018): Inhibitory Circuit Gating of Auditory Critical-Period Plasticity. *Nature Neuroscience* 21: 218–227. 639 640
- <span id="page-14-10"></span>49. Gabard-Durnam L, McLaughlin K A (2020): Sensitive Periods in Human Development: Charting a Course for the Future. *Current Opinion in Behavioral Sciences* 36: 120–128. 641 642
- <span id="page-14-11"></span>50. Margolis E T, Davel L, Bourke N J, Bosco C, Zieff M R, Monachino A D, *et al.* (2024): Longitudinal Effects of Prenatal Alcohol Exposure on Visual Neurodevelopment over Infancy. *Developmental Psychology* 60: 1673–1698. 643 644 645
- <span id="page-14-12"></span>51. Takanaga H, Ohtsuki S, Hosoya Ki n, Terasaki T (2001): GAT2/BGT-1 as a System Responsible for the Transport of Gamma-Aminobutyric Acid at the Mouse Blood-Brain Barrier. *Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism* 21: 1232–1239. 646 647 648 649
- 52. Al-Sarraf H (2002): Transport of 14C-γ-aminobutyric Acid into Brain, Cerebrospinal Fluid and Choroid Plexus in Neonatal and Adult Rats. *Developmental Brain Research* 139: 121–129. 650 651
- <span id="page-14-13"></span>53. Shyamaladevi N, Jayakumar A R, Sujatha R, Paul V, Subramanian E H (2002): Evidence That Nitric Oxide Production Increases γ-Amino Butyric Acid Permeability of Blood-Brain Barrier. *Brain Research Bulletin* 57: 231–236. 652 653 654
- <span id="page-14-14"></span>54. Vetencourt J F M, Tiraboschi E, Spolidoro M, Castrén E, Maffei L (2011): Serotonin Triggers a Transient Epigenetic Mechanism That Reinstates Adult Visual Cortex Plasticity in Rats. *European Journal of Neuroscience* 33: 49–57. 655 656 657

- <span id="page-15-0"></span>55. Gu Q, Singer W (1995): Involvement of Serotonin in Developmental Plasticity of Kitten Visual Cortex. *European Journal of Neuroscience* 7: 1146–1153. 658 659
- <span id="page-15-1"></span>56. Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Cruz V Pérez-de la (2013): Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets. *Oxidative Medicine and Cellular Longevity* 2013: 104024–104025. 660 661 662
- <span id="page-15-2"></span>57. Tavares R G, Tasca C I, Santos C E S, Wajner M, Souza D O, Dutra-Filho C S (2000): Quinolinic Acid Inhibits Glutamate Uptake into Synaptic Vesicles from Rat Brain. *NeuroReport* 11: 249–250. 663 664
- <span id="page-15-3"></span>58. Hong S Z, Mesik L, Grossman C D, Cohen J Y, Lee B, Severin D, *et al.* (2022): Norepinephrine Potentiates and Serotonin Depresses Visual Cortical Responses by Transforming Eligibility Traces. *Nature Communications* 13: 3202–3203. 665 666 667
- <span id="page-15-4"></span>59. Yano J M, Yu K, Donaldson G P, Shastri G G, Ann P, Ma L, *et al.* (2015): Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell* 161: 264–276. 668 669
- <span id="page-15-5"></span>60. Jameson K G, Hsiao E Y (2018): Linking the Gut Microbiota to a Brain Neurotransmitter. *Trends in Neurosciences* 41: 413–414. 670 671
- <span id="page-15-6"></span>61. Takesian A E, Hensch T K (2013): Balancing Plasticity/Stability across Brain Development. *Progress in Brain Research* 207: 3–34. 672 673
- <span id="page-15-7"></span>62. Madhavarao C N, Arun P, Moffett J R, Szucs S, Surendran S, Matalon R, *et al.* (2005): Defective Nacetylaspartate Catabolism Reduces Brain Acetate Levels and Myelin Lipid Synthesis in Canavan's Disease. *Proceedings of the National Academy of Sciences* 102: 5221–5226. 674 675 676
- <span id="page-15-8"></span>63. Chen T, Noto D, Hoshino Y, Mizuno M, Miyake S (2019): Butyrate Suppresses Demyelination and Enhances Remyelination. *Journal of Neuroinflammation* 16: 165–166. 677 678
- <span id="page-15-9"></span>64. Grüter T, Mohamad N, Rilke N, Blusch A, Sgodzai M, Demir S, *et al.* (2023): Propionate Exerts Neuroprotective and Neuroregenerative Effects in the Peripheral Nervous System. *Proceedings of the National Academy of Sciences of the United States of America* 120. https://doi.org/[10.1073/pnas.](https://doi.org/10.1073/pnas.2216941120) [2216941120](https://doi.org/10.1073/pnas.2216941120) 679 680 681 682
- <span id="page-15-10"></span>65. Caetano-Silva M E, Rund L, Hutchinson N T, Woods J A, Steelman A J, Johnson R W (2023): Inhibition of Inflammatory Microglia by Dietary Fiber and Short-Chain Fatty Acids. *Scientific Reports* 13: 2819–2820. 683 684 685
- <span id="page-15-11"></span>66. Barnikol U B, Amunts K, Dammers J, Mohlberg H, Fieseler T, Malikovic A, *et al.* (2006): Pattern Reversal Visual Evoked Responses of V1/V2 and V5/MT as Revealed by MEG Combined with Probabilistic Cytoarchitectonic Maps. *NeuroImage* 31: 86–108. 686 687 688
- <span id="page-15-12"></span>67. You Y, Klistorner A, Thie J, Graham S L (2011): Latency Delay of Visual Evoked Potential Is a Real Measurement of Demyelination in a Rat Model of Optic Neuritis. *Investigative Ophthalmology & Visual Science* 52: 6911–6918. 689 690 691
- <span id="page-15-13"></span>68. Gao W, Salzwedel A P, Carlson A L, Xia K, Azcarate-Peril M A, Styner M A, *et al.* (2019): Gut Microbiome and Brain Functional Connectivity in Infants-a Preliminary Study Focusing on the Amygdala. *Psychopharmacology* 236: 1641–1651. 692 693 694
- <span id="page-15-14"></span>69. Deng K, Xu J-j, Shen L, Zhao H, Gou W, Xu F, *et al.* (2023): Comparison of Fecal and Blood Metabolome Reveals Inconsistent Associations of the Gut Microbiota with Cardiometabolic Diseases. *Nature Communications* 14: 571–572. 695 696 697

- <span id="page-16-0"></span>70. Dekkers K F, Sayols-Baixeras S, Baldanzi G, Nowak C, Hammar U, Nguyen D, *et al.* (2022): An 698
- Online Atlas of Human Plasma Metabolite Signatures of Gut Microbiome Composition. *Nature* 699
- *Communications* 13: 5370–5371. 700

# 701 **Tables**

<span id="page-18-0"></span>

Educational System is divided into grades. The equivalent in terms of standards is provided in parentheses next to each mentioned grade. "University/College/Post-Matric Education" refers to tertiary or post-secondary education as defined by the World Bank. 743 744 745

bAt the time of writing (1/16/24), 1 US Dollar = 18.87 South African Rand (ZAR). 746



#### **Table 2: Longitudinal FSEA, visit-1 stool ⇨ visit-2 VEP** 747



#### **Table 3: Longitudinal FSEA, visit-1 stool ⇨ visit-3 VEP** 788



#### **Table 4: Longitudinal FSEA, visit-2 stool ⇨ visit-3 VEP** 827

#### <span id="page-22-0"></span>**Figures** 883

**Figure 1: The gut microbiome and VEP both develop over the first 18 months of life.** 884

- (A) Study design; participants (N=194) were seen up to 3 times over the first 18 months of life. Stool samples and EEG data were 885
- collected, generating microbial functional profiles (stool) and VEP waveforms (EEG) used in subsequent analyses. (B) Longitudinal 886
- sampling of study participants; Density plots (top) for stool and EEG collection show the ages represented in each visit. The scatter 887
- plot (bottom) shows individual participant visits. Dotted lines connect separate visits for the same participant. When stool and EEG 888
- data were collected for the same visit (purple) but not on the same day, dot represents the median age of collection, and vertical 889
- bars in blue and red represent stool and EEG collections respectively. (C) Principal coordinate analysis (PCoA) by multidimensional scaling (MDS) on Bray-Curtis dissimilarity of taxonomic profiles; percent variance explained (fraction of positive eigenvalues) by 890 891
- each of the first two axes are indicated on the x and y axes respectively. (D) PCoA of microbial functional profiles (UniRef90s). (E) 892
- Average (solid lines) ± standard deviation (dotted lines) for VEP waveforms at each visit. 893
- <span id="page-22-1"></span>**Figure 2: Concurrent feature set enrichment analysis of microbial neuroactive genes and VEP for three visits.** FSEA results 894
- for all genesets where at least one visit had a significant hit  $(q < 0.2)$  with at least one VEP latency (A) or amplitude (B). Dots 895
- indicate the Z-statistic from logistic regression for each gene in a gene set. Vertical bars indicate the median Z-statistic for the gene 896
- set as a whole. Y-axis position for each gene set indicates visit number. Visit 1 for inositol degradation and DOPAC synthesis were 897
- not tested, since there were fewer than 5 genes from those genesets present in the sample (See Methods). 898
- <span id="page-22-2"></span>**Figure 3: Gut microbial genes predict future VEP latencies and amplitudes.** (A) Age distributions for stool samples (left) and 899
- VEP (right) for each longitudinal comparison (same individual) tested, V1 stool →V2 VEP, V1 stool →V3 VEP, and V2 stool →V3 900
- VEP. As in [Figure 2](#page-22-1), (B) and (C) show FSEA results for all genesets where at least one visit had a significant hit (q < 0.2) with at 901
- least one VEP latency or amplitude respectively. Dots indicate the Z-statistic from logistic regression for each gene in a gene set. 902
- Vertical bars indicate the median Z-statistic for the gene set as a whole. The Y-axis position for each gene set indicates longitudinal comparison. V1 → V2 and V1 → 3 for inositol degradation and DOPAC synthesis were not tested, since there were fewer than 5 903 904
- genes from those genesets present in the sample (See Methods). 905





**A**



**A**

15

 $10$ 

5

15

 $10$ 

5

15

 $10$ 

5

age (months)

age (months)

age (months)